Xolair

Lea en español

Xolair
Xolair (the trade name for Omalizumab), is a drug that has been approved to treat teenagers and adults with severe allergic asthma since its introduction in Australia in 2002. Approved by the U.S. Food and Drug Administration (FDA) in 2014, it has been held out as being particularly effective for people who cannot be treated with H1 antihistamines or do not benefit from high doses of corticosteroids. It has also been used to treat people who suffer chronically from hives.

A number of adverse side effects have been linked to the use of Xolair, including:

  • Anaphylactic shock or anaphylaxis (a life-threatening allergic reaction)
  • Increased risk of heart disease
  • Increased risk of stroke
  • Masking of warning signs of certain cancers

If you or someone you love has suffered injury after being prescribed Xolair, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

Defective Drugs & Medical Devices Topics

Latest Articles

Four Types of Professional Malpractice

When you hear the word “malpractice,” what’s the first image that comes to mind? A doctor perf…

14 Dec 2018, Friday

Sacred Sites and Ski Resorts: The Hopi Tribe and Reclaimed Wastewater

What constitutes a “public nuisance”? And does an injury rooted in religious belief override gen…

13 Dec 2018, Thursday

Field Test Fail: When Traffic Stops Go Wrong

Traffic stops on New Year’s Eve may be a good way of deterring drunk driving, but a pair of Georgi…

12 Dec 2018, Wednesday